Video

Prostate Cancer More Likely to Recur, Kill Men Who Smoke at Diagnosis


 

FROM JAMA

The analysis also shows that current smokers made unhealthier lifestyle choices: They exercised less, drank more coffee, and had a higher intake of saturated fat and lower intake of calcium than never or former smokers. Smokers – both former and current – consumed more alcohol, but their body mass index was similar to the BMI of never smokers.

The mortality data showed a "statistically significant difference in overall survival across smoking status," at 5 and 10 years after diagnosis, the authors wrote (JAMA 2011;305:2548-2555).

Among never smokers, 89.7% were alive 5 years after diagnosis and 74.8% at 10 years; among former smokers, survival rates were slightly lower at 86.2% and 68.2%, respectively. Among current smokers they fell to 78.8% and 54.8%, respectively.

Although some studies have suggested that smokers tend to have less PSA testing and may be diagnosed at a more advanced stage, the "differential PSA screening across strata of smoking status was unlikely to fully account for our results," wrote the authors, because the percentage of men who had at least one PSA test before their diagnosis varied little among the three groups.

The authors added that direct effect of smoking on prostate cancer progression "is biologically plausible." They proposed four hypotheses: tumor promotion through carcinogens from tobacco smoke, increased plasma levels of total and free testosterone, epigenetic effects such as aberrant methylation profiles, and "nicotine-induced angiogenesis, capillary growth, and tumor growth and proliferation."

"There are very few factors that are known to increase or decrease risk of progression of prostate cancer. My goal is to find out what’s related to the rate of prostate cancer progression and what men can do to improve their chances of survival with prostate cancer," said Dr. Kenfield.

The authors reported they had nothing to disclose.

Pages

Recommended Reading

FDA Approves Abiraterone for Castration-Resistant Prostate Cancer
MDedge Internal Medicine
Radical Prostatectomy Continues to Cut Mortality After 15 Years
MDedge Internal Medicine
Two-Tiered Prostate Cancer Surveillance May Curb Overtreatment
MDedge Internal Medicine
In the Pipeline: Cabozantinib Shown to Control Tumors and Bone Metastases
MDedge Internal Medicine
Inhaled Anticholinergics May Up Urinary Retention Risk in Men
MDedge Internal Medicine
Abiraterone Prolongs Survival in Castration-Resistant Prostate Cancer
MDedge Internal Medicine
PIVOT Trial: No Overall Benefit to Radical Prostatectomy for Localized Prostate Cancer
MDedge Internal Medicine
Positive Data on Alpharadin Could Accelerate Filing Timeline
MDedge Internal Medicine
FDA Adds Warnings About High-Grade Prostate Cancer to BPH Drug Labels
MDedge Internal Medicine
Depressive Symptoms: Like Father, Like Child
MDedge Internal Medicine